

Clinical trials of acetylcysteine

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
acetylcysteine vs placebo			
Tepel , 2003 n=64/70 follow-up: 14.5 y	acetylcysteine 600 mg twice daily versus placebo	patients undergoing maintenance hemodialysis for a minimum of 3 months 3 times weekly in an ambulatory center	Parallel groups double-blind Germany

More details and results :

- antioxydants for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q131>
- antioxydants for cardiovascular prevention in patients with renal disease at <http://www.trialresultscenter.org/go-Q432>

References

Tepel, 2003:

Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. *Circulation* 2003;107:992-5 [[12600912](#)]